Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
62 participants
INTERVENTIONAL
2011-02-28
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This short induction is followed by a rituximab (375mg/m2)maintenance/ Induction schedule:Rituximab+Bendamustine on Day 1, Bendamustine on Day 2, Rituximab on Day 8, Rituximab on Day 15, rituximab on day 22, Bendamustine on Day 29, Bendamustine on Day 30 Maintenance schedule: 12 infusions of rituximab, each 8 weeks
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL
NCT01990144
Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma
NCT01523860
Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line
NCT01127841
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
NCT01234467
Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma
NCT02423837
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rituximab + bendamustine
Rituximab + bendamustine
Induction phase: rituximab and bendamustine on Day 1, Bendamustine on Day 2, Rituximab on Day 8, Rituximab on Day 15, Rituximab on Day 22, bendamustine on Day 29, Bendamustine on Day 30
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rituximab + bendamustine
Induction phase: rituximab and bendamustine on Day 1, Bendamustine on Day 2, Rituximab on Day 8, Rituximab on Day 15, Rituximab on Day 22, bendamustine on Day 29, Bendamustine on Day 30
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A minimal initial immunology is required, including : CD20, bcl-2, CD10 and CD5
* Age must be ≥ 60 years
* Patients not previously treated
* Patients with an intermediate or high risk FLIPI score requiring 2 or more of the following adverse prognostic factors:
1. Age \>60 ans
2. Ann Arbor Stage (III-IV vs. I-II)
3. Hemoglobin level ( \< 12g/dL vs. ≥ 12 g/dL)
4. Number of nodal areas (\< 5 vs. ≥ 5) (Note: LDH should not be considered as an adverse prognostic factor in this study since it is considered as high tumor burden in the GELF criteria)
* Low burden disease at study entry according to the GELF criteria
* Patients with at least one measurable site of disease: patients with only blood or marrow or splenic infiltration are excluded
* Performance status ≤ 2 on the ECOG scale
* Adequate hematological function (unless abnormalities are related to lymphoma infiltration of the bone marrow) including:
* Hemoglobin ≥ 8.0 g/dL (5.0 mmol/L)
* Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
* Platelet count ≥ 100 x 109/L
* Adequate renal function: calculated creatinine clearance \> 50 ml/min (according to MDRD method) unless these abnormalities are related to lymphoma
* Adequate hepatic function: Total bilirubin \< 2.0 mg/dl (34 µmol/L), AST (SGOT) and ALT (SGPT) ≤ 2.5 x the upper limit of normal unless these abnormalities are related to lymphoma
* Adequate cardiac function: LEVF ≥ 50% calculated by echocardiography or scintigraphy
* Having previously signed a written informed consent
Exclusion Criteria
* Grade 3b follicular lymphoma
* Patients previously on watch and wait since more than 6 months from diagnosis
* Patients previously treated for lymphoma, except splenectomy
* Patients with low FLIPI score (0 or 1 adverse prognostic factors not considering elevated LDH)
* Bulky disease at study entry according to the GELF criteria
* Presence or history of CNS disease (either CNS lymphoma or lymphomatous meningitis)
* Patients with prior or concomitant malignancies except non-melanoma skin cancer or adequately treated in situ cervical cancer or previous cancer in CR without any treatment in the last 5 years
* Positive HIV, HBV (anti-HBc positivity) and HCV serologies before inclusion
* Poor Performance status \> 2 on the ECOG scale
* Known contra-indication to study product
* Serious underlying medical conditions, which could impair the ability of the patient to participate in the trial (e.g. ongoing infection, uncontrolled diabetes mellitus, gastric ulcers, active autoimmune disease).
* Any other co-existing medical or psychological condition that will preclude participation in the study or compromise ability to give informed consent.
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Lymphoma Academic Research Organisation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pierre FEUGIER, MD
Role: PRINCIPAL_INVESTIGATOR
CHU Brabois, 54511 Vandoeuvre les Nancy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ZNA Stuivenberg
Antwerp, , Belgium
Clinique Sud du Luxembourg
Arlon, , Belgium
RHMS
Baudour, , Belgium
A. Z. Sint-Jan
Bruges, , Belgium
CHU Brugmann
Brussels, , Belgium
Université Libre de Bruxelles - Hôpital Erasme
Brussels, , Belgium
Université Catholique de Louvain Saint Luc
Brussels, , Belgium
CH Notre Dame
Charleroi, , Belgium
CHU Charleroi-Vésale
Charleroi, , Belgium
Centre de Santé des Fagnes
Chimay, , Belgium
Clinique Notre Dame de Grace
Gosselies, , Belgium
Hôpital Jolimont
Haine-Saint-Paul, , Belgium
CH Hutois
Huy, , Belgium
AZ Groeninge - Campus Maria's Voorzienigheid
Kortrljk, , Belgium
CHU Tivoli
La Louvière, , Belgium
CHR de la Citadelle
Liège, , Belgium
CHU de Liège
Liège, , Belgium
CHU Ambroise Paré
Mons, , Belgium
Clinique Saint Joseph
Mons, , Belgium
Hôpital Sainte Elisabeth
Namur, , Belgium
Heilig Hart Ziekenhuis
Roeselare, , Belgium
Centre Hospitalier de Wallonie Picarde - CHwapi
Tournai, , Belgium
CH de la Tourelle-Peltzer
Verviers, , Belgium
UCL Mt Godinne
Yvoir, , Belgium
CH du Pays d'Aix
Aix-en-Provence, , France
CHU Amiens - Hôpital Sud
Amiens, , France
CHU d'Angers
Angers, , France
CH Antibes
Antibes, , France
CH Victor Dupouy
Argenteuil, , France
CH d'Avignon - Hôpital Henri Dufaut
Avignon, , France
Hôpital de Bayonne
Bayonne, , France
Centre Hospitalier de Beauvais
Beauvais, , France
CH Jean Minjoz
Besançon, , France
CH Béziers
Béziers, , France
Centre Hospitalier de Blois
Blois, , France
Institut Bergonié
Bordeaux, , France
Polyclinique Bordeaux Nord Aquitaine
Bordeaux, , France
CH Dr Duchenne
Boulogne-sur-Mer, , France
CH de Bourg en Bresse
Bourg-en-Bresse, , France
CHU Morvan
Brest, , France
Centre Hospitalier de Brive
Brive-la-Gaillarde, , France
CHU Clémenceau
Caen, , France
Centre Francois Baclesse
Caen, , France
CH Cannes
Cannes, , France
CH Chambéry
Chambéry, , France
CH de Chartres
Chartres, , France
Hôpital de Châlon
Châlon Sur Saône, , France
Hôpital Antoine Béclère
Clamart, , France
Hôpital d'Instruction des Armées Percy
Clamart, , France
CHU Estaing
Clermont-Ferrand, , France
Pôle Santé Publique
Clermont-Ferrand, , France
CH de Compiègne
Compiègne, , France
Hôpital Sud Francilien
Corbeil Essonne, , France
Hôpital Henri Mondor
Créteil, , France
CHU le Bocage
Dijon, , France
CH de Dunkerque
Dunkirk, , France
CH Fréjus St Raphaël
Fréjus, , France
CHU Grenoble
Grenoble, , France
Centre Hospitalier de Guéret
Guéret, , France
CHD Vendée
La Roche-sur-Yon, , France
Centre Hospitalier de Laval
Laval, , France
Hôpital André Mignot
Le Chesnay, , France
Hôpital Bicêtre
Le Kremlin-Bicêtre, , France
CH Le Mans
Le Mans, , France
Clinique Victor Hugo - Centre Jean Bernard
Le Mans, , France
CHRU de Lille - Hôpital Claude Huriez
Lille, , France
CHU LIMOGES - Hôpital Universitaire Dupuytren
Limoges, , France
CH de Bretagne Sud
Lorient, , France
Clinique de la Sauvegarde
Lyon, , France
Centre Léon Bérard
Lyon, , France
Institut Paoli Calmettes
Marseille, , France
CH les Chanaux
Mâcon, , France
CH de Meaux
Meaux, , France
Ch Marc Jacquet
Melun, , France
Hôpital Notre Dame de Bon Secours
Metz, , France
CH Saint-Eloi
Montpellier, , France
CRCL Val d'Aurelle
Montpellier, , France
Centre Azuréen de Cancérologie
Mougins, , France
CHU de Mulhouse - Hôpital Emile Muller
Mulhouse, , France
Centre Catherine de Sienne
Nantes, , France
CHU Hôtel Dieu
Nantes, , France
Hôpital Américain de Paris
Neuilly, , France
Centre Antoine Lacassagne
Nice, , France
CHU de Nice
Nice, , France
CHU Caremeau
Nîmes, , France
Clinique Valdegour
Nîmes, , France
CHR de la Source
Orléans, , France
Hôpital Saint Antoine
Paris, , France
Hôpital de la Pitié Salpétrière
Paris, , France
Hôpital Necker
Paris, , France
Hôpital Hôtel Dieu
Paris, , France
Institut Curie
Paris, , France
Hôpital St Louis
Paris, , France
Hôpital Saint Antoine
Paris, , France
CH Saint Jean
Perpignan, , France
Hôpital Haut Levêque
Pessac, , France
Centre Hospitalier Lyon Sud
Pierre-Bénite, , France
CHU de Poitiers - Hôpital de la Milétrie
Poitiers, , France
CH René Dubos
Pontoise, , France
Centre Hospitalier de la Région d'Annecy
Pringy, , France
Hôpital Robert Debré
Reims, , France
Clinique de Courlancy
Reims, , France
Hôpital Pontchaillou
Rennes, , France
Centre Henri Becquerel
Rouen, , France
Clinique Mathilde
Rouen, , France
CHU Saint-Etienne
Saint Priest En Jarest, , France
Centre René Huguenin
Saint-Cloud, , France
CHG St Germain
Saint-Germain-en-Laye, , France
CH de Saint Quentin
Saint-Quentin, , France
CHU de Saint Malo
St-Malo, , France
Hôpital Font Pré
Toulon, , France
CHU Bretonneau
Tours, , France
Hôpital de Troyes
Troyes, , France
CH de Valence
Valence, , France
CHU Nancy Brabois
Vandœuvre-lès-Nancy, , France
Centre Hospitalier Bretagne Atlantique
Vannes, , France
Institut Gustave Roussy
Villejuif, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gyan E, Sonet A, Brice P, Anglaret B, Laribi K, Fruchart C, Tilly H, Araujo C, Soubeyran P, Gonzalez H, Morineau N, Nicolas-Virelizier E, Ghesquieres H, Salles B, Bouabdallah R, Orfeuvre H, Fahri J, Couturier O, Xerri L, Feugier P; Lymphoma Study Association (LYSA). Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study. Br J Haematol. 2018 Oct;183(1):76-86. doi: 10.1111/bjh.15513. Epub 2018 Aug 16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BRIEF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.